Citius pharmaceuticals announces a clinical collaboration with the university of pittsburgh to evaluate t-reg cell depletion with i/ontak (e7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a phase 1 investigator-initiated trial

I/ontak plus pd-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients university of pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022 collaboration marks second investigator-initiated study of i/ontak as combination immunotherapy cranford, n.j. , sept. 22, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a collaboration with dr. haider mahdi at the university of pittsburgh in an investigator-initiated trial to evaluate i/ontak ("denileukin diftitox" or "e7777") in combination with pembrolizumab in the treatment of recurrent or metastatic solid tumors.
CTXR Ratings Summary
CTXR Quant Ranking